Parul Bansal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Parul Bansal has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Akash Agarwal
Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, India
3 shared publications Maitreyee Panda
Department of Dermatology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India
2 shared publicationsBhabani Singh
Department of Dermatology, Siksha ‘O’ Anusandhan Institute of Medical Sciences and Sum Hospital , Bhubaneswar, Odisha
1 shared publicationBiswanath Behera
Department of Dermatology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
1 shared publication- Liza Mohapatra
Department of Dermatology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India
1 shared publication - Maitreyee Panda
Department of Dermatology, Venereology, and Leprosy, Institute of Medical Sciences and SUM Hospital, K-8 Kalinga Nagar, Bhubaneshwar, Odisha, India
1 shared publication
Latest Publications
- 8 December 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 917-920
Multiple ulcerations and fungating swellings
A 68-year-old man from rural eastern India visited the dermatology outpatient department with a 1-year history of painful swellings and ulcers. The initial swelling started on his left forearm and, subsequently, newer lesions spread to his head, neck, back and limbs.
- 8 December 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 917-920
Multiple ulcerations and fungating swellings
A 68-year-old man from rural eastern India visited the dermatology outpatient department with a 1-year history of painful swellings and ulcers. The initial swelling started on his left forearm and, subsequently, newer lesions spread to his head, neck, back and limbs.
- Open Access
- 14 August 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (5) , 835-839
Genitogluteal Porokeratoses: A Case Series of a Rare Entity
- 14 August 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (5) , 835-839
Open AccessGenitogluteal Porokeratoses: A Case Series of a Rare Entity
- 7 January 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (7) , 1312-1314
Trachyonychia secondary to pediatric alopecia areata responding to oral tofacitinib therapy: a case report and review of literature
- 7 January 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (7) , 1312-1314
Trachyonychia secondary to pediatric alopecia areata responding to oral tofacitinib therapy: a case report and review of literature
- 2 January 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (5) , 1009-1013
Modified intralesional aciclovir treatment in the management of recalcitrant palmoplantar and ungual warts: a case series of 14 patients
In this retrospective study, we evaluated the efficacy and safety of modified intralesional aciclovir for the treatment of recalcitrant palmoplantar and ungual warts in 14 patients (7 men and 7 women) of mean age 24.5 years (SD 8.19). Modified aciclovir (50 mg mL–1) was prepared by mixing 250 mg of lyophilized aciclovir powder with 4 mL of distilled water and 1 mL of 2% lignocaine. Then, this solution was injected into each wart at a dose of 0.1 mL or until blanching occurred. Every 2 weeks, the eschar was pared off and the treatment was repeated until a complete cure was observed, for a maximum of five sessions. After five sessions, 82% (n = 55/67) of warts showed a complete response, and 18% (n = 12/67) showed a partial response. Adverse effects reported included lesional tenderness for 2–3 days following injection in 23% (n = 3/13) of patients. Blistering and nail-plate damage were each seen in one patient. Modifying aciclovir treatment by adding lignocaine resulted in an unaltered concentration of aciclovir while maintaining its efficacy. The efficacy and safety were comparable with those reported for previous studies but with greater patient acceptability.
- 2 January 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (5) , 1009-1013
Modified intralesional aciclovir treatment in the management of recalcitrant palmoplantar and ungual warts: a case series of 14 patients
In this retrospective study, we evaluated the efficacy and safety of modified intralesional aciclovir for the treatment of recalcitrant palmoplantar and ungual warts in 14 patients (7 men and 7 women) of mean age 24.5 years (SD 8.19). Modified aciclovir (50 mg mL–1) was prepared by mixing 250 mg of lyophilized aciclovir powder with 4 mL of distilled water and 1 mL of 2% lignocaine. Then, this solution was injected into each wart at a dose of 0.1 mL or until blanching occurred. Every 2 weeks, the eschar was pared off and the treatment was repeated until a complete cure was observed, for a maximum of five sessions. After five sessions, 82% (n = 55/67) of warts showed a complete response, and 18% (n = 12/67) showed a partial response. Adverse effects reported included lesional tenderness for 2–3 days following injection in 23% (n = 3/13) of patients. Blistering and nail-plate damage were each seen in one patient. Modifying aciclovir treatment by adding lignocaine resulted in an unaltered concentration of aciclovir while maintaining its efficacy. The efficacy and safety were comparable with those reported for previous studies but with greater patient acceptability.